



PTO/SB/088 (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/823,253		
		Filing Date	April 12, 2004		
		First Named Inventor	REED, Jennifer		
		Art Unit	1644		
		Examiner Name	SKELDING, Zachary		
Sheet	2	of	2	Attorney Docket Number	IL402US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ZS		Kung et al., 2001, "Effect of Anti-mIL-9 Antibody on the Development of Pulmonary Inflammation and Airway..." Am. J. Respir. Cell Mol Biol. Vol 25: 600-605.	
ZS		Gruss et al., 1992, "Interleukin 9 Is Expressed By Primrary and Cultured Hodgkin and Reed-Sternberg Cells", Cancer Res. 52: 1026-1031.	
ZS		Temann et al. 1998, "Expression of Interleukin 9 in the Lungs of Transgenic Mice Causes Airway..." J. of Experimental Medicine 188(7):1307-1320.	
ZS		Abdelilah et al., 2001, "Functional Expression of IL-9 Receptor by Human Neutrophils from Asthmatic..."Am. Assoc. of Immunologists pp. 2768-2774.	

Examiner Signature	/Zachary Skelding/	Date Considered	03/06/2007
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.